Paysign (PAYS) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue increased 23% year-over-year to $15.3 million, driven by a 219% surge in pharma patient affordability programs and steady plasma business growth.

• Net income for Q3 2024 was $1.44 million ($0.03 per diluted share), up from $1.10 million ($0.02 per share) in Q3 2023.

• Adjusted EBITDA rose 20.6% to $2.83 million, with gross margin improving by 440 basis points to 55.5% due to higher-margin pharma programs.

• Ended the quarter with 478 plasma centers and 66 active patient affordability programs, reflecting ongoing expansion.

• Operating results for the nine months ended September 30, 2024, showed net income of $2.44 million, up from $0.84 million in the prior year period.

Financial highlights

• Q3 2024 gross profit was $8.47 million (up 34%), with gross margin at 55.5% versus 51.1% a year ago.

• SG&A expenses rose 32.4% to $6.2 million, reflecting investments in IT, personnel, and wage inflation.

• Adjusted EBITDA margin for Q3 2024 was 18.6%, slightly down from 18.9% year-over-year.

• Ended the quarter with $10.3 million in unrestricted cash and zero debt, after repurchasing 100,000 shares at $3.60 per share.

• Operating cash flow for the nine months ended September 30, 2024, was $8.63 million, up from $4.18 million.

Outlook and guidance

• Full-year 2024 revenue expected between $56.5 million and $58.5 million, with pharma patient affordability revenue projected at ~20% of total revenues.

• Adjusted EBITDA expected at $9–$10 million (15–17% of revenues), or $0.16–$0.18 per diluted share.

• Gross profit margin guidance remains at 54%–55%, with operating expenses projected at $30–$32 million.

• Guidance updated to include anticipated legal fees for class action and derivative lawsuit settlements in Q4, but overall results expected within prior ranges.

• Management expects available cash and forecasted revenues to sustain operations for at least 24 months.